|
**Overview**: Antinuclear Antibody IFA HEP-2 Panel**Introduction**: The Antinuclear Antibody IFA HEP-2 Panel is a diagnostic tool designed to screen for autoimmune disorders using serum samples. In India, ANA positivity is common in SLE (95-99 percent), rheumatoid arthritis, scleroderma, and other connective tissue diseases, with prevalence of autoimmune diseases rising in women. Patterns (homogeneous, speckled, nucleolar) guide further testing. High morbidity from underdiagnosis in rural areas, limited rheumatology access, and nonspecific symptoms leading to delayed therapy. Per immunology practices aligned with ICMR guidelines, the test employs HEP-2 immunofluorescence for pattern detection over 1-2 days with high sensitivity, valuable as initial autoimmune screening. This diagnostic falls under autoimmune screening and targets patients with suspected connective tissue diseases, addressing accurate detection to guide specific antibody testing. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling early identification and management. Its serum-based approach ensures reliable detection.**Other Names**: ANA IFA Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: HEP-2 substrate standard; in India, widely used in rheumatology.**Purpose**: The test screens for 2 parameters including ANA pattern to guide autoimmune assessment, detect antinuclear antibodies, inform further testing.**Test Parameters**: 1. ANA (HEP-2), 2. ANA Pattern.**Pretest Condition**: No fasting required; patients should report joint pain, rash, fatigue, Raynaud's, or photosensitivity.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on joint pain, rash, fatigue, Raynaud's, family autoimmune history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated autoimmune diseases, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunofluorescence by trained personnel to ensure sterile technique, avoid hemolysis, and interpret patterns within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive ANA indicates possible autoimmune disorder, necessitating further investigation. Negative may require follow-up if symptoms persist.**Specialist Consultation**: Rheumatologists should be consulted for management.**Additional Supporting Tests**: ENA panel or specific antibody tests for confirmation.**Test Limitations**: Low-titer positives may be nonspecific; comprehensive approach required.**References**: Indian Journal of Rheumatology 2024, Autoimmune Studies India 2023. |
